Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib in Relapsed/Refractory B-cell Lymphoma or CLL
NCT01944943Phase 2Terminated
- Sponsor
- LYSARC
- Start
- Feb 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib in B cell lymphoma, chronic lymphocytic leukemia (CLL), sponsored by LYSARC. Started Feb 2013; status: terminated.
02
Drugs
vismodegib
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01944943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01944943.